Roche of Switzerland has announced that Franz Humer, whose departure from the UK pharmaceutical company Glaxo was announced last week (Marketletter December 5), will be taking up the post of head of the pharmaceuticals division from June 1, 1995, and will be a member of Roche's corporate executive committee.
Armin Kessler, who is currently Roche's chief operating officer and head of pharmaceuticals, is to retire from the company in the middle of next year. Dr Kessler is expected to remain available as an advisor to the company and will keep his membership of the Genentech and Syntex boards of directors, according to Roche.
The reshuffle of top management at Roche has raised questions about where a successor to chairman and chief executive Fritz Gerber is likely to come from. With the departure next year of Dr Kessler, there is no obvious heir apparent.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze